This website is intended for healthcare professionals only
Specialities

Specialities

Allergic Conditions
Alopecia Areata
Atopic Dermatitis
Autoimmune Endocrine Disorders
Axial Spondyloarthritis
COVID-19
Dermatologic Conditions
Digestive Disorders
Fibromyalgia
Gout
Hematologic Disorders
Hereditary Angioedema
Hidradenitis Suppurativa
Immuno-oncology
Immunology
Inflammatory Bowel Disease
Liver Disorders
Lupus
Musculoskeletal Diseases
Neurological Disorders
Osteoarthritis
Pediatric Dermatology
Pediatric Gastroenterology
Pediatric Rheumatology
Primary Immunodeficiencies
Psoriasis
Psoriatic Arthritis
Rare Autoimmune Diseases
Respiratory Disorders
Rheumatic Diseases
Rheumatoid Arthritis
Sjogren’s Disease
Systemic Sclerosis
Urticaria
Vaccinology
Vasculitis
Vitiligo
Search

Trending Topic

Ankylosing Spondylitis
7 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Diagnosis and management of juvenile axial spondyloarthritis: Lessons and links to adult disease

Dax G Rumsey, Pamela F Weiss

At the American College of Rheumatology (ACR) Convergence 2025, Dr. Pamela Weiss delivered a focused presentation on the diagnosis and management of axial juvenile spondyloarthritis (axJSpA), highlighting key distinctions and overlaps with adult-onset disease. This targeted article synthesizes the principal objectives and takeaways from that session: identification of the characteristic clinical features of axJSpA, the […]

touchREVIEWS in RMD. 2026;6(1):Online ahead of journal publication

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin

Thomas Berg, EASL: Unmet needs in diagnosis and treatment of hepatitis

3 mins
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jul 8th 2022

touchIMMUNOLOGY spoke with Prof. Thomas Berg (University Hospital Leipzig, Leipzig, Germany; Secretary General, EASL) to discuss the burden of hepatitis, the path to diagnosis, and the current treatment options available for hepatitis B, C, and D.

Question:

  1. What are the unmet needs in diagnosis and treatment of hepatitis? (0:20)

Disclosures: Dr Thomas Berg has received grant/research support from Abbvie, Gilead, and MSD/Merck; and is on the advisory board for Abbvie, Gilead, GSK, Janssen, and MSD/Merck; and is also a speaker’s bureau participant with Abbvie, Gilead, and MSD/Merck.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Access more content from Prof. Thomas Berg

Access the latest content on hepatitis

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Rethinking MASH clinical endpoints: Is liver fibrosis the key predictor of adverse outcomes?

Zobair Younossi

Clinical trials in MASH have traditionally considered biopsy-based endpoints, MASH resolution and fibrosis improvement, as the principal measures of treatment response. However, growing recognition of fibrosis as a key predictor of adverse outcomes, coupled with advances in non-invasive assessment tools, is shaping ongoing debate about future endpoint selection. In this Q&A, we spoke with Dr Zobair Younossi about the growing importance of fibrosis as a predictor of outcomes, and the implications of prioritising fibrosis-focused endpoints in clinical trials and practice.

Advertisement

    • Related Videos in Liver Disorders

    Latest articles videos and clinical updates - straight to your inbox

    Close Popup